Please login to the form below

Not currently logged in
Email:
Password:

Actilyse

This page shows the latest Actilyse news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo licenses clot-busting antibody

Daiichi Sankyo licenses clot-busting antibody

as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

Latest news

  • NICE stroke guidance boost for Boehringer's Actilyse NICE stroke guidance boost for Boehringer's Actilyse

    NICE stroke guidance boost for Boehringer's Actilyse. Institute changes guidance on alteplase use. ... More people suffering a stroke in the UK should get treatment with Boehringer Ingelheim's thrombolytic drug Actilyse in the wake of new NICE

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics